NHS rollout of artificial pancreas narrows inequality in diabetes care
The NHS has begun providing hybrid closed‑loop artificial pancreas systems to people with type 1 diabetes in England and Wales, narrowing previous disparities in access among ethnic minorities and deprived communities. Early data show only a 3% uptake gap between the most and least deprived groups,…
The National Health Service has started offering hybrid closed‑loop artificial pancreas systems—often called life‑changing devices—to people with type 1 diabetes across England and Wales. The rollout has already begun to close long‑standing gaps in access that have historically disadvantaged ethnic minorities and residents of deprived areas.
What the device does
A hybrid closed‑loop system combines three components: a continuous glucose monitor (CGM) that tracks blood sugar, an algorithm that calculates insulin doses, and an insulin pump that delivers the calculated dose. Together, they automate much of the daily management of blood glucose, reducing the mental load of checking levels and deciding on injections, especially during meals and overnight.
Why equity matters in diabetes care
Previous technology rollouts, such as CGMs alone, have shown stark disparities. Studies found that people from minority ethnic backgrounds in England were less likely to receive CGMs, and those from deprived backgrounds often struggled to use the technology fully. These inequities have contributed to higher rates of complications, including diabetic ketoacidosis, among disadvantaged groups.
Early results show a narrowing gap
Data from the first two years of the artificial pancreas rollout indicate a remarkable shift. Uptake differed by only 3% between patients from the most and least deprived areas. Similarly, minority ethnic groups now have access rates comparable to white counterparts. This trend suggests that the NHS’s targeted approach—prioritising children first and then expanding to adults—has helped to level the playing field.
In 2023, the NHS announced that more than 150,000 adults and children with type 1 diabetes across England and Wales would be offered the device. The initial focus on children saw 32,000 of the eligible young patients fitted with pumps, representing 72.3% of those eligible. The programme will continue to roll out over the next few years until all eligible patients, both children and adults, receive the technology.
Personal stories of change
27‑year‑old Naiha Shafiq of London, who has type 1 diabetes, described the device as “life‑changing.” Prior to the pump, she experienced frequent hospital admissions for diabetic ketoacidosis and struggled with insulin injections, especially given her religious practice of wearing a hijab. The pump’s automated delivery removed the need for frequent injections and allowed her to manage her condition more comfortably and safely, even during pregnancy.
Shafiq’s experience echoes the broader benefits reported by patients: fewer hospital visits, better glucose control, and a reduction in the daily anxiety that comes with manual insulin management.
Voices from the diabetes community
Helen Kirrane, head of policy and campaigns at Diabetes UK, praised the rollout as a “significant, life‑changing difference” for thousands of people. She highlighted the role of research and advocacy in achieving an equitable distribution of the technology, while noting that some eligible patients still face barriers.
Hilary Nathan, director of policy at Breakthrough T1D, emphasized the UK’s global leadership in hybrid closed‑loop systems and called for continued focus on equitable access across all four nations. He stressed that every community should have a genuine choice in technology that best suits their needs.
Dr Clare Hambling, National Clinical Director for diabetes and obesity, highlighted the rapid implementation by paediatric diabetes teams, noting that the technology has already transformed the lives of tens of thousands of young people regardless of where they live.
What’s next for the NHS rollout
The NHS plans to extend the program to all eligible adults and children in England and Wales, with a goal of full coverage within the next few years. Ongoing monitoring will track uptake across different demographics to ensure that the initial gains in equity are maintained and expanded.
Stakeholders remain focused on removing remaining barriers—such as cost, training, and cultural sensitivities—to guarantee that every person with type 1 diabetes can benefit from this advanced technology.
As the programme evolves, the NHS will continue to collaborate with patient groups, researchers, and technology providers to refine the rollout strategy and address any emerging disparities.
Why this matters
Reducing inequality in diabetes care not only improves individual health outcomes but also lessens the long‑term burden on the health system. By ensuring that all patients, regardless of background, have access to the most effective treatment, the NHS takes a decisive step toward equitable, high‑quality care for all.
Why it matters
Closing gaps in diabetes technology access improves health outcomes for historically underserved groups and reduces the overall burden on the NHS, demonstrating a commitment to equitable care.
Key points
- Hybrid closed‑loop systems automate insulin delivery, easing daily management
- Early data show only a 3% uptake gap between most and least deprived groups
- Minority ethnic groups now have access rates similar to white counterparts
- The rollout began with children, now expanding to adults
- Stakeholders emphasize ongoing work to eliminate remaining barriers
Frequently asked questions
What is a hybrid closed‑loop system?
It combines a continuous glucose monitor, an insulin‑delivery algorithm, and an insulin pump to automate blood‑sugar management.
How many people have received the device so far?
Over 32,000 children in England and Wales have been fitted, representing 72.3% of eligible young patients.
Will adults receive the device too?
Yes, the NHS plans to offer the system to all eligible adults and children in England and Wales over the next few years.
